Survival, quality of life and breast cancer.
In recent years, evaluating quality of life (QoL) has become increasingly important as an additional measured outcome in cancer clinical trials, in particular in the field of breast cancer. This paper, after a general introduction to the present debate on the methodological issues involved in QoL evaluation, reviews results and open questions regarding the use of this measure in surgical, adjuvant and metastatic studies.
Mosconi
P
P
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. mosconi@irfmn.mnegri.it
Colozza
M
M
De Laurentiis
M
M
De Placido
S
S
Maltoni
M
M
D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000523:psychology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008408:Mastectomy; D009362:Neoplasm Metastasis / Q000628:therapy; D017063:Outcome Assessment, Health Care / Q000379:methods; D010166:Palliative Care; D011788:Quality of Life; D013629:Tamoxifen / Q000627:therapeutic use
D013629:Tamoxifen